A Phase 4 clinical trial involving cosyntropin has been marked as completed, according to a status update dated October 2, 2026. The study, registered as NCT06385509, is titled "A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months." Cosyntropin, an approved compound, was used in this trial in the context of assessing adrenal function. The trial was conducted in hypogonadal men who received JATENZO over a 12 month treatment period. According to the registry listing, the study has reached completed status at the Phase 4 stage. No results summary or outcome data were included in this status update. The listing reflects only the trial's administrative status, phase, and title as recorded. Readers interested in the study details can review the full registry entry via the provided source link. For general background on cosyntropin, including its approved uses and regulatory status, readers can consult the compound overview.
Phase 4 Cosyntropin Trial in JATENZO-Treated Men Marked Completed
See the full cosyntropin overview
Source: https://clinicaltrials.gov/study/NCT06385509